Combining oncolytic virotherapy and tumour vaccination

Cytokine and Growth Factor Reviews

Volumn 21, Issue 2-3, 2010, Pages 143-148

  Bridle, Byram W ^a   Hanson, Stephen ^a   Lichty, Brian D ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

Anti tumour immunity; Oncolytic virus; Prime:boost; Tumour vaccine

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; ADENOVIRUS VECTOR; AUTOANTIGEN; CANCER VACCINE; CD4 ANTIGEN; CD8 ANTIGEN; DENDRITIC CELL VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN; ONCOLYTIC VIRUS; PLACEBO; TUMOR ANTIGEN; VIRUS VECTOR;

ADENOVIRUS; ADOPTIVE TRANSFER; BREAST CANCER; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL TRIAL; COLON CANCER; HERPES SIMPLEX VIRUS 2; HUMAN; IMMUNE DEFICIENCY; IMMUNOLOGICAL TOLERANCE; INNATE IMMUNITY; MALIGNANT NEOPLASTIC DISEASE; METASTASIS INHIBITION; NEUROBLASTOMA; NONHUMAN; ONCOLYTIC VIROTHERAPY; POXVIRUS; PRIORITY JOURNAL; PROSTATE CANCER; REOVIRUS; REVIEW; SEMLIKI FOREST ALPHAVIRUS; SPLEEN CELL; TUMOR CELL DESTRUCTION; TUMOR IMMUNITY; TUMOR IMMUNOLOGY; VESICULAR STOMATITIS VIRUS; VIRAL GENE DELIVERY SYSTEM; VIRUS IMMUNITY; ANIMAL; GENETICS; IMMUNOLOGY; NEOPLASMS; PROCEDURES; VACCINATION;

ANIMALS; CANCER VACCINES; HUMANS; IMMUNITY, INNATE; NEOPLASMS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; VACCINATION;

EID: 77953544936     PISSN: 13596101     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cytogfr.2010.02.009     Document Type: Review

References (79)

1. Hummel J.L., Safroneeva E., Mossman K.L. The role of ICP0-Null HSV-1 and interferon signaling defects in the effective treatment of breast adenocarcinoma. Mol Ther 2005, 12:1101-1110.
2. Li H., Dutuor A., Fu X., Zhang X. Induction of strong antitumor immunity by an HSV-2-based oncolytic virus in a murine mammary tumor model. J Gene Med 2007, 9:161-169.
3. Nakamori M., Fu X., Rousseau R., Chen S.Y., Zhang X. Destruction of nonimmunogenic mammary tumor cells by a fusogenic oncolytic herpes simplex virus induces potent antitumor immunity. Mol Ther 2004, 9:658-665.
4. Li H., Dutuor A., Tao L., Fu X., Zhang X. Virotherapy with a type 2 herpes simplex virus-derived oncolytic virus induces potent antitumor immunity against neuroblastoma. Clin Cancer Res 2007, 13:316-322.
5. Endo T., Toda M., Watanabe M., et al. In situ cancer vaccination with a replication-conditional HSV for the treatment of liver metastasis of colon cancer. Cancer Gene Ther 2002, 9:142-148.
6. Toda M., Rabkin S.D., Kojima H., Martuza R.L. Herpes simplex virus as an in situ cancer vaccine for the induction of specific anti-tumor immunity. Hum Gene Ther 1999, 10:385-393.
7. Prestwich R.J., Errington F., Ilett E.J., et al. Tumor infection by oncolytic reovirus primes adaptive antitumor immunity. Clin Cancer Res 2008, 14:7358-7366.
8. Diaz R.M., Galivo F., Kottke T., et al. Oncolytic immunovirotherapy for melanoma using vesicular stomatitis virus. Cancer Res 2007, 67:2840-2848.
9. Di Paolo N.C., Tuve S., Ni S., Hellstrom K.E., Hellstrom I., Lieber A. Effect of adenovirus-mediated heat shock protein expression and oncolysis in combination with low-dose cyclophosphamide treatment on antitumor immune responses. Cancer Res 2006, 66:960-969.
10. Lapteva N., Aldrich M., Rollins L., et al. Attraction and activation of dendritic cells at the site of tumor elicits potent antitumor immunity. Mol Ther 2009, 17:1626-1636.
11. Pages F., Galon J., Dieu-Nosjean M.C., Tartour E., Sautes-Fridman C., Fridman W.H. Immune infiltration in human tumors: a prognostic factor that should not be ignored. Oncogene 2009.
12. Kaufman H.L., Kim D.W., Deraffele G., Mitcham J., Coffin R.S., Kim-Schulze S. Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma. Ann Surg Oncol 2009.
13. Rogers L.J., Eva L.J., Luesley D.M. Vaccines against cervical cancer. Curr Opin Oncol 2008, 20:570-574.
14. Lollini P.L., Cavallo F., Nanni P., Forni G. Vaccines for tumour prevention. Nat Rev Cancer 2006, 6:204-216.
15. Pilla L., Rivoltini L., Patuzzo R., Marrari A., Valdagni R., Parmiani G. Multipeptide vaccination in cancer patients. Exp Opin Biol Ther 2009, 9:1043-1055.
16. Carmichael M.G., Benavides L.C., Holmes J.P., et al. Results of the first phase 1 clinical trial of the HER-2/neu peptide (GP2) vaccine in disease-free breast cancer patients: united States Military Cancer Institute Clinical Trials Group Study I-04. Cancer 2009.
17. Ribas A., Timmerman J.M., Butterfield L.H., Economou J.S. Determinant spreading and tumor responses after peptide-based cancer immunotherapy. Trends Immunol 2003, 24:58-61.
18. Disis M.L., Wallace D.R., Gooley T.A., et al. Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer. J Clin Oncol 2009, 27:4685-4692.
19. Fishman M. A changing world for DCvax: a PSMA loaded autologous dendritic cell vaccine for prostate cancer. Exp Opin Biol Ther 2009, 9:1565-1575.
20. Madan R.A., Mohebtash M., Schlom J., Gulley J.L. Therapeutic vaccines in metastatic castration-resistant prostate cancer: principles in clinical trial design. Exp Opin Biol Ther 2009.
21. Murthy V., Moiyadi A., Sawant R., Sarin R. Clinical considerations in developing dendritic cell vaccine based immunotherapy protocols in cancer. Curr Mol Med 2009, 9:725-731.
22. Heimberger A.B., Sampson J.H. The PEPvIII-KLH (CDX-110) vaccine in glioblastoma multiforme patients. Exp Opin Biol Ther 2009, 9:1087-1098.
23. Biswas S., Eisen T. Immunotherapeutic strategies in kidney cancer-when TKIs are not enough. Nat Rev Clin Oncol 2009, 6:478-487.
24. Overwijk W.W., Tsung A., Irvine K.R., et al. gp100/pmel 17 is a murine tumor rejection antigen: induction of " self" -reactive, tumoricidal T cells using high-affinity, altered peptide ligand. J Exp Med 1998, 188:277-286.
25. Dyall R., Bowne W.B., Weber L.W., et al. Heteroclitic immunization induces tumor immunity. J Exp Med 1998, 188:1553-1561.
26. Kouiavskaia D.V., Berard C.A., Datena E., et al. Vaccination with agonist peptide PSA: 154-163 (155L) derived from prostate specific antigen induced CD8 T-cell response to the native peptide PSA: 154-163 but failed to induce the reactivity against tumor targets expressing PSA: a phase 2 study in patients with recurrent prostate cancer. J Immunother 2009, 32:655-666.
27. Miyazawa M., Ohsawa R., Tsunoda T., et al. Phase I clinical trial using peptide vaccine for human vascular endothelial growth factor receptor 2 in combination with gemcitabine for patients with advanced pancreatic cancer. Cancer Sci 2009.
28. Lubaroff D.M., Konety B.R., Link B., et al. Phase I clinical trial of an adenovirus/prostate-specific antigen vaccine for prostate cancer: safety and immunologic results. Clin Cancer Res 2009, 15:7375-7380.
29. Gridelli C., Rossi A., Maione P., Ferrara M.L., Castaldo V., Sacco P.C. Vaccines for the treatment of non-small cell lung cancer: a renewed anticancer strategy. Oncologist 2009, 14:909-920.
30. Ho V.T., Vanneman M., Kim H., et al. Biologic activity of irradiated, autologous, GM-CSF-secreting leukemia cell vaccines early after allogeneic stem cell transplantation. Proc Natl Acad Sci USA 2009, 106:15825-15830.
31. McNeel D.G., Dunphy E.J., Davies J.G., et al. Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer. J Clin Oncol 2009, 27:4047-4054.
32. Weide B., Pascolo S., Scheel B., et al. Direct injection of protamine-protected mRNA: results of a phase 1/2 vaccination trial in metastatic melanoma patients. J Immunother 2009, 32:498-507.
33. Rech A.J., Vonderheide R.H. Clinical use of anti-CD25 antibody daclizumab to enhance immune responses to tumor antigen vaccination by targeting regulatory T cells. Ann N Y Acad Sci 2009, 1174:99-106.
34. Old LJ. Cancer vaccines: an overview. Cancer Immun 2008;8(Suppl. 1):1.
35. Lonchay C., van der Bruggen P., Connerotte T., et al. Correlation between tumor regression and T cell responses in melanoma patients vaccinated with a MAGE antigen. Proc Natl Acad Sci USA 2004, 101(Suppl 2):14631-14638.
36. Harrop R., Connolly N., Redchenko I., et al. Vaccination of colorectal cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) induces immune responses which correlate with disease control: a phase I/II trial. Clin Cancer Res 2006, 12:3416-3424.
37. Amato R.J., Shingler W., Naylor S., et al. Vaccination of renal cell cancer patients with modified vaccinia ankara delivering tumor antigen 5T4 (TroVax) administered with interleukin 2: a phase II trial. Clin Cancer Res 2008, 14:7504-7510.
38. Kaufman H.L., Lenz H.J., Marshall J., et al. Combination chemotherapy and ALVAC-CEA/B7.1 vaccine in patients with metastatic colorectal cancer. Clin Cancer Res 2008, 14:4843-4849.
39. Horig H., Lee D.S., Conkright W., et al. Phase I clinical trial of a recombinant canarypoxvirus (ALVAC) vaccine expressing human carcinoembryonic antigen and the B7.1 co-stimulatory molecule. Cancer Immunol Immunother 2000, 49:504-514.
40. Jager E., Karbach J., Gnjatic S., et al. Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients. Proc Natl Acad Sci USA 2006, 103:14453-14458.
41. Harrop R., John J., Carroll M.W. Recombinant viral vectors: cancer vaccines. Adv Drug Deliv Rev 2006, 58:931-947.
42. Elzey B.D., Siemens D.R., Ratliff T.L., Lubaroff D.M. Immunization with type 5 adenovirus recombinant for a tumor antigen in combination with recombinant canarypox virus (ALVAC) cytokine gene delivery induces destruction of established prostate tumors. Int J Cancer 2001, 94:842-849.
43. Irvine K.R., Chamberlain R.S., Shulman E.P., Surman D.R., Rosenberg S.A., Restifo N.P. Enhancing efficacy of recombinant anticancer vaccines with prime/boost regimens that use two different vectors. J Natl Cancer Inst 1997, 89:1595-1601.
44. Naslund T.I., Uyttenhove C., Nordstrom E.K., et al. Comparative prime-boost vaccinations using Semliki Forest virus, adenovirus, and ALVAC vectors demonstrate differences in the generation of a protective central memory CTL response against the P815 tumor. J Immunol 2007, 178:6761-6769.
45. Hodge J.W., Poole D.J., Aarts W.M., Gomez Yafal A., Gritz L., Schlom J. Modified vaccinia virus ankara recombinants are as potent as vaccinia recombinants in diversified prime and boost vaccine regimens to elicit therapeutic antitumor responses. Cancer Res 2003, 63:7942-7949.
46. Hodge J.W., McLaughlin J.P., Kantor J.A., Schlom J. Diversified prime and boost protocols using recombinant vaccinia virus and recombinant non-replicating avian pox virus to enhance T-cell immunity and antitumor responses. Vaccine 1997, 15:759-768.
47. Marshall J.L., Hoyer R.J., Toomey M.A., et al. Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses. J Clin Oncol 2000, 18:3964-3973.
48. Kaplan J.M., Yu Q., Piraino S.T., et al. Induction of antitumor immunity with dendritic cells transduced with adenovirus vector-encoding endogenous tumor-associated antigens. J Immunol 1999, 163:699-707.
49. Ojima T., Iwahashi M., Nakamura M., et al. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen. Int J Oncol 2006, 28:947-953.
50. Boudreau J.E., Bridle B.W., Stephenson K.B., et al. Recombinant vesicular stomatitis virus transduction of dendritic cells enhances their ability to prime innate and adaptive antitumor immunity. Mol Ther 2009, 17:1465-1472.
51. Burch P.A., Croghan G.A., Gastineau D.A., et al. Immunotherapy (APC8015, Provenge) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: a Phase 2 trial. Prostate 2004, 60:197-204.
52. Small E.J., Schellhammer P.F., Higano C.S., et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 2006, 24:3089-3094.
53. Murata S., Sasaki K., Kishimoto T., et al. Regulation of CD8+ T cell development by thymus-specific proteasomes. Science 2007, 316:1349-1353.
54. Goldrath A.W., Bevan M.J. Selecting and maintaining a diverse T-cell repertoire. Nature 1999, 402:255-262.
55. Hollander G.A., Peterson P. Learning to be tolerant: how T cells keep out of trouble. J Intern Med 2009, 265:541-561.
56. Kyewski B., Derbinski J. Self-representation in the thymus: an extended view. Nat Rev Immunol 2004, 4:688-698.
57. Bennett C.L., Christie J., Ramsdell F., et al. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet 2001, 27:20-21.
58. Wildin R.S., Ramsdell F., Peake J., et al. X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy. Nat Genet 2001, 27:18-20.
59. Brunkow M.E., Jeffery E.W., Hjerrild K.A., et al. Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat Genet 2001, 27:68-73.
60. Sakaguchi S., Yamaguchi T., Nomura T., Ono M. Regulatory T cells and immune tolerance. Cell 2008, 133:775-787.
61. Lutz M.B., Kurts C. Induction of peripheral CD4+ T-cell tolerance and CD8+ T-cell cross-tolerance by dendritic cells. Eur J Immunol 2009, 39:2325-2330.
62. Shevach E.M. From vanilla to 28 flavors: multiple varieties of T regulatory cells. Immunity 2006, 25:195-201.
63. Mauri C., Ehrenstein M.R. The 'short' history of regulatory B cells. Trends Immunol 2008, 29:34-40.
64. Nakamura K., Kitani A., Fuss I., et al. TGF-beta 1 plays an important role in the mechanism of CD4+CD25+ regulatory T cell activity in both humans and mice. J Immunol 2004, 172:834-842.
65. Grutz G. New insights into the molecular mechanism of interleukin-10-mediated immunosuppression. J Leukoc Biol 2005, 77:3-15.
66. Scalapino K.J., Daikh D.I. CTLA-4: a key regulatory point in the control of autoimmune disease. Immunol Rev 2008, 223:143-155.
67. Keilholz U. CTLA-4: negative regulator of the immune response and a target for cancer therapy. J Immunother 2008, 31:431-439.
68. Sarnaik A.A., Weber J.S. Recent advances using anti-CTLA-4 for the treatment of melanoma. Cancer J 2009, 15:169-173.
69. Markiewski M.M., Lambris J.D. Unwelcome complement. Cancer Res 2009, 69:6367-6370.
70. Ostrand-Rosenberg S., Sinha P. Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol 2009, 182:4499-4506.
71. Beyer M., Schultze J.L. Regulatory T cells: major players in the tumor microenvironment. Curr Pharm Des 2009, 15:1879-1892.
72. Kelly R.J., Morris J.C. Transforming growth factor-beta: a target for cancer therapy. J Immunotoxicol 2009.
73. de la Cruz-Merino L., Henao-Carrasco F., Garcia-Manrique T., Fernandez-Salguero P.M., Codes-Manuel de Villena M. Role of transforming growth factor beta in cancer microenvironment. Clin Transl Oncol 2009, 11:715-720.
74. Vigil A, Martinez O, Chua MA, Garcia-Sastre A. Recombinant Newcastle disease virus as a vaccine vector for cancer therapy. Mol Ther 2008.
75. Chuang C.M., Monie A., Wu A., Pai S.I., Hung C.F. Combination of viral oncolysis and tumor-specific immunity to control established tumors. Clin Cancer Res 2009, 15:4581-4588.
76. Stockinger B., Barthlott T., Kassiotis G. The concept of space and competition in immune regulation. Immunology 2004, 111:241-247.
77. Kedl R.M., Kappler J.W., Marrack P. Epitope dominance, competition and T cell affinity maturation. Curr Opin Immunol 2003, 15:120-127.
78. Lichty BD, Bridle BW, Wan Y. Potentiating cancer immunotherapy using an oncolytic virus. The fifth international meeting on replicating oncolytic virus therapeutics, Banff Alberta; March 2009.
79. Wagner D.H. Re-shaping the T cell repertoire: TCR editing and TCR revision for good and for bad. Clin Immunol 2007, 123:1-6.